Accelrys Signs $29M in New Licensing Deals | GenomeWeb

NEW YORK, Feb. 24 (GenomeWeb News) - Accelrys yesterday said that in the three months ending Dec. 31, 2005, it entered into "a number of comprehensive, multi-year agreements with some of the world's largest pharmaceutical companies."

The agreements include licenses for Accelrys' computational software and informatics platform totaling $29 million over the term of the agreements, said Accelrys in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.